Harnessing Global Minds: An International Collaboration for Rare Diseases Diagnosis

Charlotte Kalafut

Pittsburgh, PA (June 27, 2024) Asher Orion Group, a key player in the field of medical informatics innovation, is at the forefront of a pioneering international initiative aimed at transforming the diagnosis of rare diseases through the power of Artificial Intelligence (AI) and Federated Learning. Collaborating with esteemed institutions such as the University of Cambridge and Mass General Brigham, we are excited to contribute to the development of innovative diagnostic tools for Birt-Hogg-Dube (BHD) Syndrome. This rare genetic condition, which impacts the skin, lungs, and kidneys, presents significant diagnostic challenges that our collective expertise is well-equipped to address.


Our multinational team, comprising clinicians, computer scientists, and AI specialists, is united by a shared vision to harness clinical data and advanced machine learning techniques. Supported by the Myrovlytis Trust's generous grant, we are utilizing a federated learning platform provided by Rhino Health to construct a set of AI algorithms to assist in the diagnosis of BHD Syndrome. This state-of-the-art approach enables us to build models using data from diverse geographic locations while maintaining the privacy and security of the data within its home institutions.


At Asher Orion Group, we are personally driven by our own experience and struggle for a rare disease diagnosis. John F Kalafut, PhD has dedicated his career to improving health outcomes through technology, developing over 20 innovative AI enterprise medical products and 40 patents for large companies and healthcare institutions.  Today, as industry insiders running a global boutique consulting firm, we have helped dozens of companies with their medical AI products and market strategies.


“This is a unique opportunity to combine expertise from across the globe, both clinicians and computer science expertise. We strive for the day when all physicians and care-teams can access and use the power of computational innovations for patients’ quality of life regardless of their geographical location and socio-economic status. In my career, I have participated in and led several international consortia charged with developing medical AI innovations. Based on those experiences, I can affirm that this research can serve as a model for future research into rare diseases.” Said John F Kalafut, PhD, CEO of Asher Orion Group.


We are honored to be part of this groundbreaking research and are optimistic about the positive impact it will have on increasing diagnosis rates for BHD Syndrome. Through this collaboration, we aim to empower healthcare providers with the right tools and knowledge, ultimately leading to a future where patients have timely access to the medical support and advice they need.


Patient Advocacy Video regarding the importance of research: Link


About The Myrovlytis Trust

The Myrovlytis Trust is a charity (UK Charity Commission number 1122073) founded in 2007, with an aim is to transform the outlook for rare conditions. With an initial focus on Birt-Hogg-Dubé Syndrome and osteosarcoma, the trust strategically funds research directed towards new treatments. To learn more, visit https://myrovlytistrust.org.